RxDoctor Payments Data

Holly Fike, NP

Family · Liverpool, NYNPI 1861788929

Payments from drug & device makers

$14,143in general payments, 2019–2025

Across 899 payments — averaging $15.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • Abbott$819
  • GSK$811
  • AstraZeneca$685
  • plus $7K from 52 others

What the payments were for

  • Food & beverage$14,124100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie145$2,136
Novo Nordisk145$1,804
Lilly USA, LLC101$1,310
Abbott43$819
GSK58$811
AstraZeneca21$685
Pfizer37$572
Bayer28$569
Amgen41$518
Boehringer Ingelheim29$439
Otsuka America Pharmaceutical, Inc.23$431
Gilead10$250
Johnson & Johnson16$240
Merck14$229
Biohaven Pharmaceutical Holding Company Ltd.13$211
Takeda Pharmaceuticals U.S.A., Inc.12$200
Amarin Pharma, Inc.13$188
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC15$167
Kowa Pharmaceuticals America, Inc.11$166
Novartis7$157
Teva Pharmaceuticals USA, Inc.7$146
Biohaven Pharmaceuticals, Inc.9$144
Phathom Pharmaceuticals, Inc.10$136
Astellas Pharma US Inc6$132
Almatica Pharma LLC7$129
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$123
Exact Sciences7$113
Idorsia Pharmaceuticals US Inc5$109
Avanir Pharmaceuticals, Inc.4$107
Lundbeck LLC5$88
Kyowa Kirin, Inc.3$69
Madrigal Pharmaceuticals2$67
Axsome Therapeutics, Inc.4$65
Sanofi-aventis U.S. LLC3$63
Sun Pharmaceutical Industries Inc.3$54
Sumitomo Pharma America, Inc.3$51
Otsuka Pharmaceutical Development & Commercialization, Inc.1$48
Grifols USA, LLC3$47
Amneal Pharmaceuticals LLC2$44
Shield Therapeutics Inc2$42
Esperion Therapeutics, Inc.3$41
Edwards Lifesciences1$38
Clarus Therapeutics Inc.2$37
Corcept Therapeutics2$36
Paratek Pharmaceuticals, Inc.2$35
Inspire Medical Systems, Inc.1$33
Dexcom, Inc.1$31
Collegium Pharmaceutical, Inc.2$30
IBSA Pharma Inc.2$30
Verona Pharma, Inc.1$22
Acadia Pharmaceuticals Inc1$21
Arbor Pharmaceuticals, Inc.1$18
Boston Scientific1$17
Mylan Specialty L.p.1$17
Optinose US, Inc.1$16
Nevro Corp.1$16
Nestle Healthcare Nutrition Inc.1$14
Fidia Pharma USA Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,143 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$73,588
Medicare patients
182
Services billed
2,644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide98$145,145
Trelegy ElliptaFluticasone/Umeclidin/Vilanter107$93,651
TrulicityDulaglutide38$56,554
RybelsusSemaglutide23$53,704
JardianceEmpagliflozin40$51,731
MounjaroTirzepatide30$49,286
EliquisApixaban47$48,843
RexultiBrexpiprazole17$33,832
Tresiba Flextouch U-200Insulin Degludec19$32,133
FarxigaDapagliflozin Propanediol17$26,035
JanuviaSitagliptin Phosphate15$24,070
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$13,943
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$10,337
XareltoRivaroxaban12$6,796
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,804$198,849121 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$811$106,252135 claims
Lilly USA, LLCTrulicity, Mounjaro$1,310$105,84068 claims
Boehringer IngelheimJardiance$439$51,73140 claims
PfizerEliquis$572$48,84347 claims
AstraZenecaFarxiga, Breztri Aerosphere$685$39,97837 claims
Otsuka America Pharmaceutical, Inc.Rexulti$431$33,83217 claims
MerckJanuvia$229$24,07015 claims
Johnson & JohnsonXarelto$240$6,79612 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$44$1,913188 claims
AbbVieSynthroid$2,136$1,61937 claims
Almatica Pharma LLCSertraline Hcl$129$1,422141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in Liverpool

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →